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ABSTRACT 
Infections with the 2009 pandemic influenza A(HlNl) virus often leads to acute 
respiratory distress syndrome (ARDS) in high-risk patients. In these patients , ARDS has a 
mortality rate of 40-50 % [1]. Patients may die before any intervention is possible since 
there are few if any early biomarkers that are indicative of ARDS and can be used for 
diagnosis . In a search for biomarkers that signal early disease progression in mice, multiple 
acute phase proteins involved with inflammatory responses to infectious stimuli were 
proposed . Three biomarkers were evaluated for this project. These included C-reactive 
protein (CRP) , Serum Amyloid A (SAA) and Transferrin. To validate these biomarkers as 
predictors of ARDS , mice were infected with the influenza A Califomia/04 /2009 
(H 1 N 1 )pdm09 virus and serum was collected from infected mice at different time points 
(0 - 72 hours post infection). Serum samples were tested for amounts of CRP, SAA and 
Transferrin using an enzyme-linked immunosorbent assay (ELISA) . Control mice were 
mock-infected and tested alongside for comparison. Our results indicate that of the three 
biomarkers tested , SAA shows strong potential as an early indicator of ARDS with a peak 
at 72 hours post infection in infected mice serum . Further investigation is in progress to 
observe the levels of SAA past day 3 (72 hours post infection). 
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INTRODUCTION 
In April of 2009 , a novel influenza A(HlNl) virus strain, shown in Figure 1, emerged in 
Mexico , and quickly spread worldwide . The World Health Organization (WHO) declared 
this virus outbreak a pandemic in June of 2009 [l]. Eight months later, 59 million 
estimated illnesses , 265 ,000 hospitalizations , and 12,000 deaths were reported within the 
United States [2]. The first pandemic of the 21st century is now over, but the novel HlNl 
virus is still circulating worldwide as the major cause of seasonal influenza disease [3]. 
Figure 1: False-color negative stained transmission electron microscope image oflnfluenza A 
(HIN I )pdm09 virus particles . (Source of the micrograph , 
http ://en.wikipedia .org/wiki /lnfluenza _A_ virus_subtype _ H l N l) [ 4] 
Seasonal influenza is an acute, contagious respiratory infection caused by 
influenza A and B viruses [5]. Most patients do not need hospitalization and present with 
mild symptoms to the viruses. However , some high-risk patients (the elderly , the young, 
pregnant women , and people with immunodeficiency and/or other medical conditions) 
can develop Acute Respiratory Distress Syndrome (ARDS) and require admittance to the 
intensive care unit [6]. ARDS is a life-threatening , fast progressing lung condition that 
can develop 24 to 48 hours after onset of illness and has a mortality rate of 40 - 50% [2]. 
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It causes fluid buildup inside the lungs and thus prevents enough oxygen from getting 
into the blood and other vital organs [6]. ARDS symptoms include difficulty breathing, 
low blood pressure , as well as kidney and liver failure. Some surviving patients later 
suffer from memory loss caused by brain damage. Often, people with ARDS are so sick, 
they cannot complain about their symptoms . Since patients with ARDS show no clinical 
evidence of elevated arterial or pulmonary capillary pressure, accurately diagnosing 
ARDS before it is too late for intervention has proven to be difficult. Thus , the 
development of biomarkers that could be used to diagnose ARDS more accurately and 
early in disease progression is vital. 
Biomarkers are biological molecules found in blood , and other body fluids, 
indicating normal or abnormal processes of conditions or disease states [7]. Biomarkers 
used to show disease progression are usually the result of inflammation or immune 
system response to an infection . Preliminar y unpublished data has indicated that an 
inflammator y regulatory protein , Interleukin-6 (IL-6) , could be a potential early 
biomarker indicating the severity of influenza virus infection . Elevated levels of IL-6 
were associated with severe disease in patients hospitalized with HlNl virus infection 
[8]. Serum IL-6 levels associated strongly with the requirement of critical care admission 
and were predictive of fatal outcome. Preliminary studies performed at the Institute for 
Antiviral Research (IAR) at Utah State University with influenza virus-infected mice 
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Figure 2: Interleukin (IL-6) levels in serum samples of control mice (blue line) and mice 
challenged with varying doses of Influenza A (HIN I )pdm09 virus (red lines) . 
As the search for suitable biomarkers continues, three particular biomarkers that 
could potentially indicate early ARDS progression were tested in the mouse model. 
These biomarkers included C-reactive protein (CRP) , Serum Amyloid A (SAA) and 
Transferrin. C-reactive protein is a pentameric , acute-phase protein that binds to 
phosphocholine found on damaged cells to facilitate phagocytosis by macrophages [9]. 
Levels of CRP have been reported to increase in the serum during inflammation caused 
by various diseases including viral infections [1 O]. Serum Amyloid A (SAA) is an acute-
phase apolipoprotein , whose function is not yet well understood [11]. It has been shown 
that concentrations of SAA also increase within the serum during inflammation [ 11]. 
Transferrin is a glycoprotein that reversibly binds to free iron within the serum. 
Transferrin was demonstrated to be a negative acute-phase protein , which means that 
levels of transferrin were found to decrease with inflammation in humans [12]. In mice 
however , transferrin is a positive acute-phase protein , much like CRP and SAA. 
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MATERIAL and METHODS 
Animals and Experimental Design 
One hundred 8-to-12-week old female mice of the BALB/c strain were used in the 
experiment to model human influenza virus infections. All mice were comparable in 
weight (18-20 g). Fifty mice were infected with 90 µL of influenza A/Califomia/04 /2009 
(H1Nl)pdm09 virus - a virus associated with ARDS in both mice and humans. Five mice 
were put in 10 groups, each group for serum collection at one of ten different time points 
(0, 4, 8, 12, 16, 20, 24, 36, 48, and 72 hours post infection (HPI) . A 1:150 dilution of the 
virus , corresponding to a 90% lethal dose , was prepared in PBS (phosphate buffered 
saline - a carrier solution). The virus was administered intranasall y by placing a 90 µL 
drop of virus solution on the nose after the mice were anesthetized with 100 µL of 
ketamine/xylazine (50 mg/kg/5 mg/kg) . Fifty mice were sham-infected with 90 µL of 
PBS only, using the same inoculation method. 
After infection , blood samples were collected from mice at 0, 4, 8, 12, 16, 20, 24, 
36, 48, and 72 hours post infection (HPI) through cheek bleeding targeting the 
mandibular blood vessel as shown in Figure 3. 
Figure 3: Target submandibular blood vessel used to collect blood samples at 0, 4, 8, 12, 16, 20, 
24, 36, 48 , and 72 hours post sham and virus infections. Picture courtesy of Braintree Scientific 
Inc. [13] 
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Serum samples were separated from blood and frozen at -80°C. After the last 
serum collection, infected mice were euthanized and their lungs were collected and 
homogenized for virus titration, also known as an endpoint dilution assay, to confirm the 
viral infection of infected mice. To guarantee sufficient sample volume for all proposed 
tests , serum samples from each animal per time point were later pooled, aliquoted and 
stored at -80°C until further use. 
Virus Titration (Endpoint Dilution Assay) 
Virus titration was performed through the endpoint dilution assay by observing virally-
induced cytopathic effects in Madin Darby canine kidney (MOCK) cells. Ninety-six-well 
plates were seeded with approximately 40,000 cells per well and grown overnight to 
confluency at 37°C and 5% CO2. The next day, plates were washed twice with 100 µL 
infection medium (MEM/EBSS supplemented with 10,000 U/ml trypsin , 1 µL/ml EDT A, 
50 µL/ml gentamycin). Wells were filled with 100 µL infection medium. Serum samples 
were diluted ten-fold in infection medium , then 100 µL of each dilution was added into 
wells as shown in Figure 4. Each sample was titered in quadruplicates . After 6 days 
incubation at 37°C and 5% CO2, MOCK cells were microscopically observed for 
cytopathic effect (CPE) caused by the virus present (Figure 5). The virus dose ( or virus 
titer) that was able to infect 50% of the cell culture (CCIDso) was calculated by the Reed-
Muench method [14]. The virus titer is reported as log10 CCIDso/0.1 mL. 
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Figure 4: Endpoint dilution assay plate diagram on which samples are serially diluted from 10-1 
to I 0-8. After 6 days of incubation, each well is microscopically analyzed for virally induced 
effects and scored as either plus or minus. The numbers of infected wells are used to calculate 
virus titer values. 
A 
Figure 5: Example of virally-induced cytopathic effects of MOCK cells observed under the light 
microscope. A) Typical appearance of healthy cells forming a mono layer. B) Rounded off cells 
indicate cell death caused by the virus . This well would be scored as ' plus ' . 
Enzyme-Linked Immunosorbant Assay (ELISA) 
Serum samples were analyzed for levels of C - reactive protein (CRP) , Serum Amyloid A 
(SAA) and Transferrin using commercially available enzyme-linked immunosorbent 
assays (ELISA). Assay protocols and deviations are briefly described below. 
The enzyme-linked immunosorbant assay (ELISA) is an immunological test that 
uses antibodies specific to a target molecule coupled with colorimetric changes that occur 
after binding of the target molecule with the antibodies to isolate and quantify the target 
molecule. The principle features of an ELISA are shown in Figure 6. 
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Figure 6: Sandwich ELISA procedure steps that use antibodies to signal the amount of protein 
present in a sample. Picture courtesy of Sung J . H. et al. [15] 
A 96-well microtiter plate is coated with a capture antibody specific to the protein 
of interest. Samples are added to this plate , and the protein of interest in the sample is 
given time, usually at room temperature , to bind to the immobilized antibodies . Unbound 
proteins and other contaminants are washed away in a wash step. A second antibody is 
added which also binds to the protein/molecule of interest , thereby forming a sandwich 
and trapping the protein of interest. The second antibody is linked to an enzyme which 
will produce a colorful substance once it is provided with its specific substrate. The 
amount of the colorful substance in solution can be measured with a spectrophotometer 
as the absorbance of that solution and is related to the amount of captured 
protein/molecule of interest. The exact amount of the protein of interest can be 
mathematically interpolated from absorbance values obtained from a standard curve. 
CRP ELISA 
Two CRP ELISA experiments were performed according to manufacturer ' s suggestions 
(Life Diagnostics, Inc ., Cat. # 2210-1 ). Initially , three micro liters of serum from each 
samples was used to make 1: 100, 1:320, and 1: 1000 dilutions of the serum that were 
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tested on a 96-well ELISA plate. The 1 :320 dilution samples were run in duplicates . On 
the second ELISA experiment, the optimal 1 :320 dilution samples were tested in 
quadruplicate. Wash steps were performed with 250 µL of wash solution instead of the 
suggested 400 µL to avoid overspill from the wells . The number of wash steps was 
consequently increased from 6 to 7. 
SAA ELISA 
Three SAA ELISA experiments were carried out as described by the manufacturer in 
Mouse Serum Arnyloid A (SAA) ELISA test kit (Life Diagnostics , Inc. , Cat. # 3400-1 ). 
Four micro liters of serum from each sample was used and two dilutions , 1: 100 and 1 :320, 
were initially tested . For the second ELISA , 3 µL of serum was used to test dilutions 
1: 100, 1 :320 and 1: 1000. On third ELISA experiment , 3 µL of serum was used to test 
SAA levels in the following dilution s: 1 :320 ; 1: 1000; 1: 3,200 ; 1: 10,000; 1: 32,000 ; 
1: 100,000 , and 1: 320 ,000 . As with the CRP ELISA , wash steps were performed with 
250 µL, and the number of wash steps was consequently increased from 4 to 8. 
Transferrin ELISA 
Transferrin ELISAs were done the same as outlined in the protocol in Mouse Transferrin 
ELISA test kit (Life Diagnostics , Inc., Cat. # 3450-1 ) . Two microliters of serum from 
each sample was used , and 1: 100,000; 1 :320 ,000 and 1: 1,000 ,000 dilutions were tested. 
Samples were run in singles except for the 1 :320,000 dilution, which was run in 
duplicates. Wash steps were increased from 6 to 8. 
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Data Analysis 
The samples were prepared as suggested by the ELISA kit instructions. Absorbance at 
450 nm was measured with a spectrophotometer. ELISA data were analyzed by 
comparing differences in biomarker absorbance between control and infected mice . 
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RESULTS and DISCUSSION 
Virus Titration (Endpoint Dilution Assay) 
Serum samples collected at later hours post infection had higher viral titers than those 
collected earlier (Figure 7). Virus titers of serum collected from mice in groups 1 (0 HPI) 
and 3 ( 4 HPI) were below the detection limit of the assay ( <0.67 log,o CCIDso/0.1 ml). 
Almost all serum samples collected at 8 HPI or later showed increased virus titers 
confirming that the mice were successfully infected with influenza A(H 1Nl)pdm09 
virus. Serum samples collected at 48 HPI showed lower virus titer average because only 
one mouse out of the five in the group showed a high virus titer result (7.67) while the 
other four had virus titer below the detection limit( < 0.67). This may be attributed to 
errors in infecting the mice or performing viral titration. Individual virus titers can be 
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Figure 7: Mean virus titers (reported as log10 CClDs o/0.1 mL) of serum samples collected from 
five infected mice per group. Samples were collected at 0, 4, 8, 12, 16, 20 , 24, 36, 48, and 72 
hours post infection (HP!) . Asterisk at 48 HP! indicates potential technical error during mice 
infection or virus titration. Refer to Appendix tables 1 A and 1 B for average and individual titer 
data tables. 
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Enzyme-Linked Immunosorbant Assay (ELISA) 
CRP ELISA 
Control samples showed an infection-like curve with a peak between 12 and 36 hours in 
the serum samples that were diluted 1: 100 (Figure 8a). However, at 72 HPI, infected 
serum samples had greater levels of CRP than did the control mice. More optimal 
absorbance results were obtained from samples diluted 1 :320, where control mice sera 
have minimal levels of CRP while infected mice sera showed a drastic increase in CRP 
levels at time points 48 and 72 HPI (Figure 8b ). The third dilution evaluated (1: 1000) was 
too diluted and absorbance levels were too low to draw any conclusions (Figure 8c ). CRP 
concentrations in serum samples could not be quantified due to inconsistencies in the 
absorbance values for the standard . 
Interestingly , we could not replicate the results in a second ELISA experiment 
using the same samples (Figure 9). Both infected and control samples show an increase in 
CRP levels simultaneously starting from 48 HPI. However , this trend only continues for 
infected samples . At 72 HPI, CRP levels were higher for infected samples compared to 
control samples. Overall absorbance levels also decreased as compared to the first ELISA 
experiment. This could be due to potential degradation of CRP during extended storage at 
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Figure 8: Absorbance readings from the first ELISA experiment for mouse CRP in serum 
samples from influenza virus-challenged (red) and control mice (blue) as measured 450 nm. (a) 
Samples were diluted I: I 00 and were run as singles . (b) Samples were diluted I :320 . Samples 
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Figure 9: Absorbance readings from the second ELISA experiment for mouse CRP in serum 
samples from influenza virus-challenged and control mice as measured at 450 nm . Samples were 




SAA appears to be a strong biomarker candidate. In the first experiment, serum samples 
collected from control animals showed only a baseline absorbance reading (Figures 1 Oa 
and 1 Ob) with minor fluctuations in the first 36 hours post sham-infection. Serum samples 
collected from virus-infected animals, however, indicated a clear increase in SAA 
starting at 48 HPI with a peak at 72 HPI. 
A second experiment with samples diluted with dilutions 1: 100, 1 :320, and 
1: 1,000 was performed to validate that SAA was a good potential biomarker (Figures 
11 a, 11 and 11 c ). As expected from the first experiment, infected samples showed higher 
concentrations of SAA at 72 HPI in all dilutions, although minimal peaks could also be 
observed at 20 HPI in control samples . 
In both experiments, absorbance values did not decrease with increased dilutions 
of samples at 72 HPI, indicating that SAA concentrations were too high for the 
spectrophotometer to detect the difference (Figures 1 Oa, 1 Ob and 11 a, 11 b and l lc ). To 
further observe the effect of dilution on absorbance reading and to obtain a viable dilution 
factor that can be used in further investigations, a third ELISA test was performed. As 
shown in Figure 12, sera diluted higher than 1: 1000 show greater differences in 
absorbance for the time point of interest , 72 HPI. If sera were diluted any further than 
1 :32,000 SAA levels were too diluted for detection. To avoid high and low ends of 
absorbance levels that cannot be detected by the spectrophotometer, the dilution 1: 10,000 
was selected as an optimal dilution factor for future ELISAs . The estimated concentration 
of SAA at 72 HPI was 2,428 µg/mL (1: 10,000 dilution) with the 4-parameter regression 
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Figure 10: Absorbance readings from the first ELISA experiment for mouse serum amyloid A 
(SAA) samples from infected (red) and uninfected mice (blue). Values represent the mean of 
duplicates . (a) Serum samples were diluted I : I 00 in assay diluent. (b) Serum samples were 
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Figure 11: Absorbance readings from the second ELISA experiment for mouse serum amyloid A 
(SAA) samples from infected (red) and uninfected mice (blue) . (a) Serum samples were diluted 
I: I 00 in assay diluent and were run in singles. (b) Serum samples were diluted I :320 in assay 
diluent and were run in duplicates . Values represent the mean of duplicates . (c) Serum samples 
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Figure 12: Absorbance values from the third ELISA experiment of serum samples collected at 48 
and 72 HPI diluted in half logs from I :320 to I :320,000 to show the effect of dilution and fine 
tune the best dilution factor . 
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Transf errin ELISA 
In the sera of infected mice, transferrin concentrations showed a sharp peak at 16 HPI 
followed by a return to base levels . The peak was about twice as high as in serum 
samples taken from control animals at the same time point. This trend could be observed 
from all three tested dilutions (1: 100,000; 1 :320,000; 1: 1,000,000) . Some absorbance 
readings at 1: 1,000,000 dilution of sample were out of range (Figure 13c ). Except for the 
time points 16 and 20 HPI, the transferrin concentrations in serum samples from control 
animals were actually higher than those levels in sera taken from infected animals . Thus 
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Figure 13: Absorbance readings for Transferrin of mouse serum samples from infected (red) and 
uninfected mice (blue). (a) Serum samples were diluted I: I 00,000 in assay diluent and run as 
singles. (b) Samples were diluted I :300,000 and run in duplicates. The mean of duplicate 
readings is shown . ( c) Samples were diluted I: 1,000 ,000 in assay and run as singles . Yellow-
filled markers indicate out-of-range readings . 
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CONCLUSIONS 
The most promising biomarkers (CRP, SAA, and Transferrin) are presented and 
discussed in this thesis in detail. Their assessment , along with four other biomarkers 
(Complement Factor 3, Hydrogen Peroxide , Alpha 2, 6 - sialyltransferase and 
Prostaglandin Ei) tested in the project as potential early indicators of ARDS , are listed in 
Table 1. 
Table 1: Summary of tested biomarkers and their potential as early indicators of ARDS. Seven 
biomarkers (CRP, SAA, Transferrin , Complement factor 3, H20 2, alpha 2,6-sialyltransferase, and 
prostaglandin E2) were tested for their potential use as early indicators of ARDS . Biomarkers 
shaded in grey are discus sed in this thesis . 
Biomarker tested 
C-Reactive Protein (CRP) 
Serum Amyloid A (SAA) 
Transferrin 
Complement Factor 3 (CF3) 
Hydrogen Peroxide (H20 2) 
Alpha 2,6-s ialyltran sferase 
Prostaglandin E2 








The 72-HPI peak observed in the first CRP ELISA experiment could not be replicated in 
the second CRP ELISA experiment where samples were diluted with the ideal dilution of 
1 :320 and tested in quadruples. Thus, CRP does not appear to be a good potential early 
indicator of ARDS . 
SAA proved to be a strong biomarker candidate for early detection of ARDS on 
day 3 (72 HPI) of infection. Serum collected from control mice show a baseline of SAA 
levels while those of infected mice show a steep increase of SAA after 48 HPI. This 
makes SAA an ideal biomarker . Further experiments are in progress to evaluate the levels 
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of SAA after 72 HPI. Changes in SAA levels in mice that have been treated with 
effective antiviral drugs should also be evaluated to further correlate SAA levels with 
ARDS. 
At this point, it is not certain whether transferrin is a good biomarker candidate. 
Although infected mouse serum showed a much earlier peak in transferrin at 16 HPI, the 
validity of the peak seems questionable since control samples appear to have higher 
transferrin concentrations than infected samples at later time points. 
In summary , SAA has been found to be the most promising biomarker that could 
be used for the early detection of ARDS in mice. Further experimentation is underway to 
measure SAA levels after 72 HPI. To further correlate SAA levels with ARDS , the 
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APPENDIX 
Table Al: Average virus titers (log10 CCID 5o/0. I mL) of serum samples collected from five infected mice in 
ten different groups. Each group was assigned to one time point at which serum was collected (0, 4 , 8, 12, 
16, 20, 24 , 36, 48 , and 72 hours post infection , HP!). 
Mouse group ID Serum collection (HPI) Average virus titer Standard deviation 
I 0 < 0.67 0.00 
3 4 < 0.67 0.00 
5 8 2.33 0.59 
7 12 3.43 0.65 
9 16 4.47 0.36 
11 20 5.30 0.27 
13 24 5.43 0.49 
15 36 6.57 0.59 
17 48 2.07* 3. 13 
19 72 6.63 1.33 
*Low virus titer may be attributed to technical errors in mice infection or viral titration . 
Table A2: Individual virus titers (log1o CCID 5o/0. I mL) of serum samples collected from five infected mice 
in ten different groups from which serum was collected at 0, 4, 8, 12, 16, 20, 24 , 36, 48 , and 72 hours post 
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Group Serum collection Mouse Virus titer Average group Standard 
ID (HPI) ID per mouse virus titer deviation 
7 I 3.50 
7 2 4.33 
7 12 7 3 2 .50 3.43 0.65 
7 4 3.50 
7 5 3.33 
9 I 4.50 
9 2 5.00 
9 16 9 3 4.50 4.47 0.36 
9 4 4.00 
9 5 4.33 
11 I 5.50 -
11 2 5.00 
11 20 11 3 5.00 5.30 0.27 
11 4 5.50 
11 5 5.50 
13 I 5.67 -
13 2 4 .67 
13 24 13 3 5.50 5.43 0.49 
13 4 5.33 
13 5 6.00 
15 I 6.67 
15 2 5.67 
15 36 15 3 6.67 6.57 0.59 
15 4 7.33 
15 5 6.50 
17 I < 0.67 
17 2 < 0.67 
17 48 17 3 < 0.67 2.07 3.13 
17 4 < 0.67 
17 5 7 .67 
19 I 7.33 
19 2 7.50 
19 72 19 3 7.33 6.63 1.33 
19 4 4.33 
19 5 6.67 
